{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T02:40:31Z","timestamp":1719715231157},"reference-count":59,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bulcan.2023.05.011","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T17:38:08Z","timestamp":1696959488000},"page":"675-686","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["N\u00e9phroprotection\u00a0: principes g\u00e9n\u00e9raux et application au patient de canc\u00e9rologie\u00a0\u2013\u00a0quand la protection du rein est indispensable \u00e0 la bonne conduite du plan de soin oncologique"],"prefix":"10.1016","volume":"111","author":[{"given":"Matthieu","family":"Bainaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Try","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Zaidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2023.05.011_bib0305","series-title":"Conforme \u00e0 la r\u00e9forme des ECNi-EDN","article-title":"N\u00e9phrologie","author":"Moulin","year":"2020"},{"issue":"1","key":"10.1016\/j.bulcan.2023.05.011_bib0310","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/kisup.2011.32","article-title":"Section 2: AKI definition","volume":"2","author":"KDIGO 2012","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.bulcan.2023.05.011_bib0315","series-title":"Ma maladie r\u00e9nale chronique 2022-10\u00a0propositions pour d\u00e9velopper la dialyse \u00e0 domicile [Internet]","author":"Soci\u00e9t\u00e9 francophone de nephrologie dialyse et transplantation","year":"2022"},{"issue":"3","key":"10.1016\/j.bulcan.2023.05.011_bib0320","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021\u00a0clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.bulcan.2023.05.011_bib0325","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","article-title":"Cancer and renal insufficiency results of the BIRMA study","volume":"103","author":"Janus","year":"2010","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.bulcan.2023.05.011_bib0330","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s10147-020-01715-9","article-title":"Association between chronic kidney disease and mortality in stage IV cancer","volume":"25","author":"Ishii","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2023.05.011_bib0340","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","article-title":"Risk factors for end-stage renal disease: 25-year follow-up","volume":"169","author":"Hsu","year":"2009","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.bulcan.2023.05.011_bib0345","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2023.05.011_bib0350","doi-asserted-by":"crossref","first-page":"9585","DOI":"10.1200\/jco.2009.27.15_suppl.9585","article-title":"Impact of renal insufficiency on cancer survival: results of the IRMA-2\u00a0study","volume":"27","author":"Launay-Vacher","year":"2009","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.bulcan.2023.05.011_bib0355","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1053\/j.ackd.2021.10.007","article-title":"Chronic kidney disease in cancer survivors","volume":"28","author":"Lee","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"10.1016\/j.bulcan.2023.05.011_bib0360","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.urology.2012.04.064","article-title":"Effect of testicular germ cell tumor therapy on renal function","volume":"80","author":"Cost","year":"2012","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.bulcan.2023.05.011_bib0365","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2023.05.011_bib0370","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ajkd.2021.05.012","article-title":"Incidence and predictors of CKD and estimated GFR decline in patients receiving immune checkpoint inhibitors","volume":"79","author":"Chute","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.bulcan.2023.05.011_bib0505","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.nephro.2017.06.006","article-title":"N\u00e9phrotoxicit\u00e9 m\u00e9dicamenteuse","volume":"14","author":"Izzedine","year":"2018","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.bulcan.2023.05.011_bib0375","first-page":"1","article-title":"Development and validation of a new equation based on plasma creatinine and muscle mass assessed by CT scan to estimate glomerular filtration rate: a cross-sectional study","volume":"0","author":"Stehl\u00e9","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.bulcan.2023.05.011_bib0380","first-page":"1","article-title":"New and old GFR equations: a European perspective","volume":"0","author":"Delanaye","year":"2023","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.bulcan.2023.05.011_bib0385","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1053\/j.ajkd.2013.03.027","article-title":"Update on cystatin c: incorporation into clinical practice","volume":"62","author":"Shlipak","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.bulcan.2023.05.011_bib0390","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.lpm.2011.04.021","article-title":"Les promesses de la n\u00e9phroprotection \u00e0 l\u2019\u00e9preuve des faits","volume":"40","author":"Krummel","year":"2011","journal-title":"Presse Med"},{"issue":"13","key":"10.1016\/j.bulcan.2023.05.011_bib0395","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1042\/CS20200307","article-title":"Unravelling the tangled web of hypertension and cancer","volume":"135","author":"Sionakidis","year":"2021","journal-title":"Clin Sci"},{"issue":"5","key":"10.1016\/j.bulcan.2023.05.011_bib0400","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1053\/j.ackd.2021.09.008","article-title":"Acute kidney injury in patients with cancer: a review of onconephrology","volume":"28","author":"Gudsoorkar","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"10.1016\/j.bulcan.2023.05.011_bib0405","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.ackd.2021.09.011","article-title":"Onco-hypertension: an emerging specialty","volume":"28","author":"Gudsoorkar","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.bulcan.2023.05.011_bib0410","series-title":"Hypertension: from basic research to clinical practice [Internet]","article-title":"Impact of salt intake on the pathogenesis and treatment of hypertension","author":"Rust","year":"2016"},{"issue":"3","key":"10.1016\/j.bulcan.2023.05.011_bib0415","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11764-015-0429-z","article-title":"The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients: results from the PROFILES registry","volume":"9","author":"Vissers","year":"2015","journal-title":"J Cancer Surviv"},{"issue":"7","key":"10.1016\/j.bulcan.2023.05.011_bib0420","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/dme.13919","article-title":"Challenges in the management of people with diabetes and cancer","volume":"36","author":"Chowdhury","year":"2019","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.bulcan.2023.05.011_bib0425","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00125-019-04991-x","article-title":"Trends in cancer mortality among people with vs without diabetes in the USA, 1988\u20132015","volume":"63","author":"Harding","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.bulcan.2023.05.011_bib0430","series-title":"Recommandation de bonne pratique \u2013 strat\u00e9gie m\u00e9dicamenteuse du contr\u00f4le glyc\u00e9mique du diab\u00e8te de type 2 [Internet]","author":"Ertel-Pau","year":"2013"},{"key":"10.1016\/j.bulcan.2023.05.011_bib0435","series-title":"Frontiers of hormone research [Internet]","doi-asserted-by":"crossref","DOI":"10.1159\/000513807","article-title":"Diabetes in cancer patients: risks, goals and management","author":"Ragni","year":"2021"},{"key":"10.1016\/j.bulcan.2023.05.011_bib0440","series-title":"End of life guidance for diabetes care \u2013 trend diabetes [Internet]","author":"Sinclair","year":"2021"},{"key":"10.1016\/j.bulcan.2023.05.011_bib0445","series-title":"Guide du parcours de soins\u00a0\u2013\u00a0maladie r\u00e9nale chronique de l\u2019adulte (MRC)","first-page":"85","author":"Nathalie","year":"2021"},{"issue":"9","key":"10.1016\/j.bulcan.2023.05.011_bib0450","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1093\/ndt\/gfq138","article-title":"Physical exercise among participants in the Dialysis Outcomes and Practice Patterns Study (DOPPS): correlates and associated outcomes","volume":"25","author":"Tentori","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2023.05.011_bib0455","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/hdi.12564","article-title":"Physical function was related to mortality in patients with chronic kidney disease and dialysis: PA was related mortality in CKD and dialysis patients","volume":"21","author":"Morishita","year":"2017","journal-title":"Hemodial Int"},{"issue":"19","key":"10.1016\/j.bulcan.2023.05.011_bib0460","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1200\/JCO.21.00102","article-title":"Sarcopenia in the older adult with cancer","volume":"39","author":"Williams","year":"2021","journal-title":"JCO"},{"issue":"21","key":"10.1016\/j.bulcan.2023.05.011_bib0465","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.1002\/cam4.3428","article-title":"Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies","volume":"9","author":"Xia","year":"2020","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.bulcan.2023.05.011_bib0470","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40620-020-00840-y","article-title":"Sarcopenia in chronic kidney disease: what have we learned so far?","volume":"34","author":"Sabatino","year":"2021","journal-title":"J Nephrol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.05.011_bib0475","doi-asserted-by":"crossref","first-page":"F1188","DOI":"10.1152\/ajprenal.00012.2018","article-title":"Twelve-week combined resistance and aerobic training confers greater benefits than aerobic training alone in nondialysis CKD","volume":"314","author":"Watson","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.05.011_bib0480","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/jcsm.12775","article-title":"Home-based aerobic exercise and resistance training for severe chronic kidney disease: a randomized controlled trial","volume":"12","author":"Uchiyama","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.bulcan.2023.05.011_bib0485","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020\u00a0update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.bulcan.2023.05.011_bib0490","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000481209","article-title":"Tobacco use: a chronic kidney disease accelerant","volume":"46","author":"Leonberg-Yoo","year":"2017","journal-title":"Am J Nephrol"},{"issue":"7","key":"10.1016\/j.bulcan.2023.05.011_bib0495","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2215\/CJN.11121017","article-title":"Self-reported tobacco, alcohol, and illicit drug use and progression of chronic kidney disease","volume":"13","author":"Bundy","year":"2018","journal-title":"CJASN"},{"issue":"595","key":"10.1016\/j.bulcan.2023.05.011_bib0500","first-page":"418","article-title":"Quelle place pour l\u2019\u00e9ducation th\u00e9rapeutique en n\u00e9phrologie\u00a0?","volume":"14","author":"Dufey Teso","year":"2018","journal-title":"Rev Med Suisse"},{"issue":"2","key":"10.1016\/j.bulcan.2023.05.011_bib0510","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2015.115","article-title":"Phenotype standardization for drug-induced kidney disease","volume":"88","author":"Mehta","year":"2015","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.bulcan.2023.05.011_bib0515","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A systematic review of strategies to prevent cisplatin-induced nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.bulcan.2023.05.011_bib0520","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/1060028014533303","article-title":"Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol","volume":"48","author":"Morgan","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.bulcan.2023.05.011_bib0525","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.bulcan.2023.05.011_bib0530","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"JASN"},{"issue":"2","key":"10.1016\/j.bulcan.2023.05.011_bib0535","first-page":"7","article-title":"Manifestations vasculaires et r\u00e9nales des anti-angiog\u00e9niques\u00a0; classification et prise en charge","volume":"10","author":"Halimi","year":"2015","journal-title":"e-VEGF-IMMUNO-actu"},{"issue":"5","key":"10.1016\/j.bulcan.2023.05.011_bib0540","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/j.ackd.2021.09.003","article-title":"Nephrotoxicity from molecularly targeted chemotherapeutic agents","volume":"28","author":"Kala","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"10.1016\/j.bulcan.2023.05.011_bib0545","first-page":"198","article-title":"[Renal failure and renal symptoms associated with molecular targeted therapies in oncology]","volume":"71","author":"Rousseau","year":"2021","journal-title":"Rev Prat"},{"issue":"2","key":"10.1016\/j.bulcan.2023.05.011_bib0550","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.bulcan.2023.05.011_bib0555","doi-asserted-by":"crossref","first-page":"e0188975","DOI":"10.1371\/journal.pone.0188975","volume":"12","author":"Lin","year":"2017","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.bulcan.2023.05.011_bib0560","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nephro.2020.12.006","article-title":"Les inhibiteurs du SGLT2\u00a0: une nouvelle \u00e8re pour nos patients","volume":"17","author":"Halimi","year":"2021","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.bulcan.2023.05.011_bib0565","series-title":"Du bon usage des inhibiteurs des SGLT2\u00a0en n\u00e9phrologie clinique. Collection fiche pratique de la SFNDT","author":"Delanaye","year":"2022"},{"issue":"7","key":"10.1016\/j.bulcan.2023.05.011_bib0570","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2\u00a0inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"10.1016\/j.bulcan.2023.05.011_bib0575","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bulcan.2023.05.011_bib0580","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2\u00a0diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2023.05.011_bib0585","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2\u00a0diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.05.011_bib0590","unstructured":"Buysschaert M, Preumont V. Les inhibiteurs des SGLT-2 dans la prise en charge du diab\u00e8te de type 2. Louvain m\u00e9dical, 2018 :4; 506-509."},{"issue":"3","key":"10.1016\/j.bulcan.2023.05.011_bib0595","article-title":"The EMPEROR-Reduced trial: SGLT2\u00a0inhibitors for heart failure get more support","volume":"2020","author":"Wagdy","year":"2020","journal-title":"Glob Cardiol Sci Pract [Internet]"},{"issue":"22","key":"10.1016\/j.bulcan.2023.05.011_bib0300","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2\u00a0diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T02:03:27Z","timestamp":1719713007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123002953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":59,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0007455123002953"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.05.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N\u00e9phroprotection\u00a0: principes g\u00e9n\u00e9raux et application au patient de canc\u00e9rologie\u00a0\u2013\u00a0quand la protection du rein est indispensable \u00e0 la bonne conduite du plan de soin oncologique","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}